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Abstract 13 
The incidence and severity of Clostridium difficile infections (CDI) has been increased 14 
not only among hospitalized patients, but also in healthy individuals traditionally 15 
considered as low risk population. Current treatment of CDI involves the use of 16 
antibiotics to eliminate the pathogen, although recurrent relapses have also been 17 
reported. For this reason, the search of new antimicrobials is a very active area of 18 
research. The strategy to use inhibitors of toxin´s activity has however been less 19 
explored in spite of being a promising option. In this regard, the lack of fast and reliable 20 
in vitro screening methods to search for novel anti-toxin drugs has hampered this 21 
approach. The aim of the current study was to develop a method to monitor in real time 22 
the cytotoxicity of C. difficile upon the human colonocyte-like HT29 line, since 23 
epithelial intestinal cells are the primary targets of the toxins. The label-free, impedance 24 
based RCTA (real time cell analyser) technology was used to follow overtime the 25 
behaviour of HT29 in response to C. difficile LMG21717 producing both A and B 26 
toxins. Results obtained showed that the selection of the medium to grow the pathogen 27 
had a great influence in obtaining toxigenic supernatants, given that some culture media 28 
avoided the release of the toxins. A cytotoxic dose- and time-dependent effect of the 29 
supernatant obtained from GAM medium upon HT29 and Caco2 cells was detected. 30 
The sigmoid-curve fit of data obtained with HT29 allowed the calculation of different 31 
toxicological parameters, such as EC50 and LOAEL values. Finally, the modification in 32 
the behaviour of HT29 reordered in the RTCA was correlated with the cell rounding 33 
effect, typically induced by these toxins, visualized by time-lapsed captures using an 34 
optical microscope. Therefore, this RTCA method developed to test cytotoxicity 35 
kinetics of C. difficile supernatants upon IEC could be a valuable in vitro model for the 36 
screening of new anti-CDI agents. 37 
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1. Introduction 39 
Clostridium difficile is a Gram-positive, spore forming, anaerobic bacterium that 40 
inhabits the large intestine of healthy individuals. However, when the intestinal 41 
microbiota is disturbed (e.g. administration of oral antibiotics) this microorganism is 42 
able to overgrowth leading to different pathologies, such as C. difficile infections (CDI) 43 
in humans and animals (Rupnik et al., 2009). The main mechanism of virulence in C. 44 
difficile is related to the production of the two large protein toxins TcdA (308 kDa) and 45 
TcdB (260 kDa) and some variants are also able to produce the binary CDT toxin 46 
(Rupnik, 2008). Both A and B toxins have the same enzymatic activity, although TcdA 47 
acts mainly as enterotoxin whereas TcdB has a broad cytotoxic activity. Both toxins act 48 
as glycosyltransferases inactivating host cell GTPases, then causing disruption of the 49 
actin cytoskeleton and leading to colonocyte death via apoptosis; this produces a loss of 50 
intestinal epithelial barrier function by opening tight junctions between cells, which 51 
increased intestinal permeability and fluid accumulation, followed by the onset of 52 
diarrhoea (Jank and Aktories, 2008; Voth and Ballard, 2005). Toxins also induce the 53 
release of cytokines which lead to the activation of neutrophils, mast cells, enteric 54 
nerves and sensory neurons within the intestinal lamina propria. These, in turn, induce 55 
the release of neuropeptides and pro-inflammatory cytokines resulting in an 56 
inflammatory response and pseudomembrane formation (Shen, 2012; Sun et al., 2015). 57 
C. difficile is responsible for 20 to 30% of antibiotic-associated diarrhoea and is 58 
the most frequent in nosocomial diarrhoea (Abou-Chakra et al., 2014). The CDI 59 
manifestation ranges from asymptomatic carriage to clinical problems: from mild 60 
diarrhoea to more severe disease syndromes, including abdominal pain, fever and 61 
leucocytosis. Fulminant or severe complicated CDI is characterized by inflammatory 62 
lesions and the formation of pseudomembranes in the colon, toxic megacolon or bowel 63 
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perforation, sepsis, shock and death (Faris et al., 2010). CDI have traditionally been 64 
assumed to be restricted to health-care settings. However, it is known that certain 65 
environments, animals and foods are predictable sources of C. difficile, although 66 
zoonotic and foodborne transmissions have not been confirmed yet (Rodriguez-Palacios 67 
et al., 2013). The main groups of risk are elders hospitalized and patients after 68 
hospitalization receiving antibiotics. However, CDI is increasing in younger 69 
populations, with no previous contact either with the hospital environment or with 70 
antibiotics, and in specific populations that were previously considered of low risk, such 71 
as children and pregnant women (Carter et al., 2012). In the recent years, the incidence 72 
and mortality of CDI has significantly increased due to the emergence in North America 73 
and Europe of strains with increased virulence, or hyper-virulent isolates, belonging to 74 
restriction endonuclease type BI, North American pulsed-field type 1 and PCR-ribotype 75 
027. In addition, emerging strains belonging to PCR-ribotype 017 and 078, which are 76 
also associated with severe disease, have been isolated in parts of Asia and Europe 77 
(Bouillaut et al., 2013; Drudy et al., 2007; Kim et al., 2008). Hyper-virulent strains are 78 
characterized by significantly production of more A and B toxins and by their resistance 79 
to fluoroquinolones; they often produce more spores, in comparison to historical strains, 80 
and they synthesise the binary toxin CDT (C. difficile transferase) belonging to the 81 
family of binary ADP-ribosylating toxins (Gerding et al., 2014; Schwan et al., 2014). 82 
 Therapies against CDI comprise the use of antibiotics such as metronidazole or 83 
vancomycin, however in some cases this treatment does not prevent for the relapse of 84 
CDI. Emerging therapeutic options are currently under investigation for treatment of 85 
CDI (Mathur et al., 2014); in this regard, it is of pivotal relevance the use of fast, 86 
reliable, and accurate methods allowing the screening of new potential agents against C. 87 
difficile toxicity. This was the aim pursued in the current work, in which intestinal 88 
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cellular lines were used as biological model to follow in real time the toxic effect of a C. 89 
difficile strain producing both A and B toxins.   90 
 91 
2. Material and methods 92 
2.1. C. difficile culture conditions and quantification of toxins 93 
T  type strain C. difficile LMG21717 (~ATCC
®
9689, Ribotype 001, genes tcdA+tcdB, 94 
c-) producing both TcdA and TcdB toxins (Toxinotype 0) was purchased from the 95 
	
 	
 	  	
	  , Belgium) and the 96 
nn-toxigenic strain C. difficile ATCC
®
43601 (Ribotype 031, genes tcdA-, tcdB-, cdtB-) 97 
 f ﬀ	
 Type Culture Collection” (Manassas, VA, USA). Both strains were 98 
rﬁﬂ
inely grown (for 16 h) in Reinforced Clostridium Medium [RCM, Oxoid, Thermo 99 
Fisher Scientific Inc., Waltham, MA] in Hungate tubes. Incubations took place at 37ºC 100 
under anaerobic conditions (80% N2, 10% CO2, 10% H2) in a MG500 chamber (Don 101 
Whitley Scientific, West Yorkshire, UK). Several broth media (Table 1, supplementary 102 
Table S1) and incubation periods (24, 48, 72 and 120 h) were tested to select the best 103 
conditions for survival and toxigenic activity. The OD (600 nm), pH and counts, made 104 
in each corresponding medium supplemented with 2% agar, were measured to follow C. 105 

dﬃﬃd
c
d  activity. To determine cytotoxicity, bacterial cultures at the selected conditions 106 
wr !nﬂr"#ﬁ$% &'()***xg, 10 min) to collect supernatants and pellets. Supernatants 107 
wr %"r!ﬂ+, ﬂ-ﬂ%) w r.- /++ﬂ- wr w.- % n- w"ﬂ  078 9ﬁ##r .n%108 
r-ﬁ-/n%%
(1/10 of the initial culture volume) in McCoy´s medium which is defined 109 
9+w
.  110 
The concentration of A and B toxins produced by C. difficile LMG21717 111 
-ﬁ/rn.ﬂ.nﬂ
 was determined by independent ELISA tests (tgcBIOMICS GmbH, Bingen, 112 
Germany) following the manufacturer´s instructions. 113 
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 114 
2.2. Cell-line cultures 115 
The intestinal epithelial cell (IEC) lines HT29 (ECACC 91072201) and Caco2 (ECACC 116 
86010202) were purchased from the “European Collection of Cell Cultures” (Salisbury, 117 
UK) and stored at IPLA under liquid N2. Both cell lines were maintained under standard 118 
conditions using two specific media: supplemented McCoy´s medium (or MM), for 119 
HT29, and supplemented Dulbecco´s modified Eagle medium (or DMEM), for Caco2 120 
(Hidalgo-Cantabrana et al., 2014). Both media were added, as well, with a mixture of 121 
antibiotics (50 mg/ml streptomycin-penicillin, 50 mg/ml gentamicin and 1.25 mg/ml 122 
.a/ ﬂr"!"n B). All media and reagents were purchased from Sigma-Aldrich (Sigma-123 
Aldrich Co., St. Louis, MO). For maintenance, the cell lines were incubated at 37°C, 124 
5% CO2 atmosphere in a CO2-Series Shel-Lab incubator (Sheldon Manufacturing Inc., 125 
OR, USA) and were weekly trypsinized. A few consecutive passages were used: from 126 
p146 to p148, for HT29, and from p47 to p48, for Caco2. Cells were grown in 25 cm
2
 127 
bottles with vented (0.2 mm membrane) cap (Falcon®, Corning Inc. Life Science, 128 
Tewksbury, MA) and after 5 or 7 days of incubation these cultures were used to harvest 129 
cells for the real time experiments.  130 
 131 
2.3. Monitoring cell-line behaviour in real-time 132 
The RTCA (real time cell analyser) xCELLigence equipment (ACEA Bioscience Inc., 133 
8.n S"$) ;<
), which monitors three independent 16-well E-plates (each well having 134 
ﬂ  -.a
surface than 96-well standard plates), was used to test the behaviour of the IEC 135 
(Hidalgo-Cantabrana et al., 2014). The equipment was introduced in a Heracell-240 136 
Incubator (Thermo Electron LDD GmbH, Langenselbold, Germany), set at 37°C with 137 
5% CO2 atmosphere, and it was connected with a computer that controls and records the 138 
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RTCA-curves. Initially, both IEC were titrated to determine the number of cells needed 139 
for further experiments. A cell suspension (1x10
6 
cell/ml) was made in the 140 
corresponding medium for each IEC and, afterwards, serial ½ dilutions were prepared. 141 
Finally, 200 ml of the different cell suspensions were seed, in duplicated wells, in two 142 
independent 16-well E-plates (Fig. 1A). These micro-plates were hold in the equipment 143 
and incubated at 37ºC, 5% CO2 to record the cell index (CI) every 15 min, for 50 h. The 144 
CI is an arbitrary unit that indicates variations of the impedance in gold-145 
microelectrodes, placed in the bottom of the E-plates, as consequence of the IEC 146 
attachment and growth as well as due to morphological changes. 147 
 148 
2.4. Monitoring the cytotoxic effect of C. difficile upon IEC  149 
To analyse the cytotoxic effect of C. difficile LMG21717 both IEC were used in 150 
confluent (monolayer) state and the standard working parameters were defined 151 
accordingly to the titration results (Fig. 1B). An initial number of 2x10
5
 cells (in 100 ml) 152 
were seed per well, thus allowing the formation of a monolayer around 14-15 h post-153 
seeding. After 7-8 h of post-confluent state (around 22 h of total incubation) culture 154 
medium was removed; then different C. difficile samples (in 200 ml) were added and the 155 
monitoring continued (every 10 min) for additional 23±1 h under the standard 156 
incubation conditions. The duration of a typical experiment was 44 h, which ends with 157 
t>? @AtA ABACDEFE GAHHF?@ IJt KFt> t>? RTCA software 1.2.1 (ACEA Bioscience). Data 158 
BIHL
alization was performed as follows; first, the normalized-CI at a given time point 159 
KAE GACGJCAt?@
M
D @F
N
F@FB
O
t>?
PQ
At t>FE
R
IFBt
M
D t>?
PQ
At t>? BIHLACF
U
AtFIB tFL?
R
IFBt
160 
K>FG>
V
FB IJH GAE?
V
KAE t>?
W
FHEt tFL? LIBFtIH?@ FLL?@FAt?CD A
W
t?H
C. difficile 161 
EJ
R
?HBAtABt A@@FtFIB
s
tFL? CA
R
E?@
XY
LFB
Z[ \
>JE
at the normalization time-point the 162 
BIHL
alized-CI is equal 1 for all wells. Afterwards, all data were referred to the “baseline 163 
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^_` be ghbijklimop iqu ovjxkymzu{-CI of each well from the normalized-CI baseline, 164 
K>FG> FB IJH GAE? KAE t>? GIBtHIC
s
GJCtJH? L?@FJL KFt>IJt
C. difficile supernatant 165 
A@@FtFIB
Z|
t>JE
V
t>? BIHLACF
U
?@
-CI of the control is the “0 line” that is showed in the 166 
W
F
O
JH?E I
W
t>? H?EJCtE E?GtFIB
[   167 
 168 
2.5. Image monitoring in real-time conditions 169 
The compact, inverted, optical microscope LumaScope-600 Series (Etaluma, Carlsbad, 170 
CA) with a 40x objective was used to visualize, in time-lapsed capture images, the toxic 171 
effect of C. difficile samples under culturing conditions. For that purpose, the 172 
microscope was introduced in the Heracell-240 Incubator and was connected with an 173 
external computer that captures the images, every 10 
LFB
, by means of the 174 
LumaView600Cy 13.7.17.0 software (Etaluma). An optical quality (equivalent to 175 
coverslip no. 1.5), standard bottom m-Slide 2-well plate (Ibidi GmbH, Martinsried, 176 
Germany) was used to monitor the formation of the HT29 monolayer after initially 177 
E??@FB
O 1 ml of 2x10
6
 cells/ml suspension (Fig. 1C). Once that the confluent state was 178 
reached, and at the time defined with the RTCA-DP equipment (~22 h), MM 179 
supplemented with 2.5% C. difficile supernatant (collected from 48 h cultures in GAM) 180 
was added and the image capture continued for additional 24 h.      181 
 182 
2.6. Statistical analysis 183 
The statistical package IBM SPSS Statistics for Window Version 22.0 (IBM Corp., 184 
Armonk NY) was used to asses differences in response (normalized CI) of HT29 due to 185 
the supernatant dose by means of one-way ANOVA test. Afterwards, differences among 186 
doses were determined by the Duncan mean comparison test which allowed identifying 187 
the LOAEL (lowest observed adverse effect level) and NOAEL (non-observed adverse 188 
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effect level) doses (Jeffery et al., 2004). Finally, the EC50 (concentration at which the 189 
half of the maximum adverse effect was detected) at a defined time point was calculated 190 
by the RTCA software 1.2.1 (ACEA Bioscience) from the normalized-CI vs. log 191 
concentration data fitted to a sigmoidal-curve.  192 
 193 
3. Results 194 
 C. difficile LMG21717 cultures in GAM has the highest toxic effect upon HT29  195 
The initial step to develop a method to follow in real-time the cytotoxic activity of the 196 
tIFBItD
R
?
Y C. difficile strain upon IEC was obtaining a toxigenic supernatant. For that 197 
R
JH
R
Ise, eight different media and four sampling points were screened. The strain 198 

X

X
 KAE BIt A
M
C? tI EJH
N
F
N
?
V
At ABD FBGJ
M
AtFIB
 time, in RCM, BHI-C, BHI-199 

J
RR
C
, or BHI-C-FSB after 48 h incubation (Table 2). In the remaining media, the 200 
highest counts (>1x10
7
 CFU/ml) were reached at this incubation period, whilst longer 201 
periods led to a reduction in the bacterial counts (data no shown). To test the toxigenic 202 
capability of C. difficile, the behaviour of HT29 in presence of 20% supernatants (Fig. 203 
2A) or pellets (Fig. 2B) collected from the cultures in different media and incubation 204 
periods, was monitored in real-time. The CI values obtained were normalized by the 205 
control sample (MM without C. difficile factors) and by the time at which the factors 206 
were added. The lowest normalized-CI value indicates the highest toxigenic capability 207 
of C. difficile factors upon HT29 since the reduction of this unit reflects the detachment 208 
of the cell line, from the gold-microelectrode in the E-plate, or modifications in the 209 
morphology of the cell-line monolayer. For practical purposes, we have arbitrary set the 210 
point of 4-h after factor addition, to obtain numeric values allowing comparisons among 211 
factors s\
A
M
C? 
Z[ In agreement with the absence of growth, both supernatants and 212 
pellets collected from 48-h cultures in RCM, BHI-C, BHI-Suppl, or BHI-C-FSB 213 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
}} 
 
showed the highest normalized CI values along all monitored period (Fig. 2A and B) or 214 
at the defined 4-h point (Table 2). Remarkably, the pellet harvested from BHI medium 215 
retained all toxigenic activity, since its corresponding supernatant showed a normalized-216 
CI near cero. An intermediate pattern was denoted for C. difficile grown in 217 
RCM+BHI+FSB given that produced the most toxigenic pellet, but being able to release 218 
part of the toxins to the supernatant. Finally, the two media containing GAM produced 219 
the more toxic supernatants and also their corresponding pellets showed low 220 
normalized-CI values, i.e. high toxicity. In order to be able to choose one of these two 221 
GAM media, the normalized-CI after 4-h was calculated for both factors harvested from 222 
grown cultures after 72 and 120 h of C. difficile incubation. The supernatant collected 223 
from GAM, without supplementation, showed the highest toxigenic capability which 224 
remained stable during prolonged C. difficile culturing periods (Fig. 2C). Therefore, as 225 
conditions to obtain toxigenic supernatants for further experiments we have selected 226 
cultivation of C. difficile LMG21717 in GAM medium for 48 h. The concentration of 227 
toxin A and toxin B quantified under these conditions was 210±51 ng/ml and 16±8 228 
ng/ml, respectively. The supernatant collected from these culture conditions was stored 229 
at -80ºC until its use, since we have detected that higher temperature (-20ºC) of storage 230 
reduced the activity of the supernatants (data no shown). 231 
 232 


 C. difficile LMG21717 toxic effect is dose dependent  233 
Next, we aimed at determining whether the toxigenic effect was dependent on the 234 
amount of supernatant added and if was maintained during prolonged periods. To 235 
achieve this goal experiments upon HT29 monolayers were performed using a wide 236 
supernatant-percentage range. Immediately after the supernatant addition, it is 237 
noticeable the increase in the impedance (CI) signal, which it can be easily followed in 238 
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t>? BIHLACF
U
?@-CI graphic (Fig. 3A). The maximum normalized-CI values are reached 239 
around 45 min after supernatant addition, the highest being at the highest doses (CI > 240 
0.05 for concentrations above 2.5%). This behaviour is related with changes in the 241 
morphology and shape of the eukaryotic cells. Afterwards, the CI signal showed a 242 
continuous reduction over time and after 2 h, the CI recorded for most concentrations 243 
tested started to show negative values. The normalized-CI drop was more drastic at 244 
higher supernatant concentrations, as indicated the higher slopes obtained in the 245 
BIHLalized-CI vs. time curves. This behaviour suggests a loss in the monolayer 246 
integrity, which could be due to a disruption of the tight junctions between adjacent 247 
cells, to cellular death, or to a combination of both events. The sigmoid-curve fit (R
2
 = 248 
0.9941) of normalized-CI vs. log concentration (percentages) obtained 4-h after 249 
supernatants addition, clearly demonstrated the toxigenic dose-dependent effect of the 250 
  supernatant upon HT29 monolayers (Fig. 3B). Using this fit the LOAEL, i.e. 251 
the lowest concentration of C. difficile supernatants that produced a detectable toxic 252 
effect (p<0.05), was 0.0781% which corresponded to 164 and 12.5 pg/ml of TcdA and 253 
TcdB, respectively. Therefore, the NOAEL, or the highest concentration of supernatant 254 
tested that causes no toxic effect, was 0.0391% (390.8 ppm). The concentration 255 
inducing half of the maximum effect (EC50 dose) was 0.6206% (1304 and 99 pg/ml for 256 
TcdA and TcdB, respectively). After longer periods of co-incubation (22-h) the 257 
different doses of C. difficile supernatants still had a stronger toxigenic effect upon 258 

\
 G?CCE
V
AE t>? CIK?H BIHLACF
U
?@
-CI values reached indicates (Table 3). Finally, 259 
A
iming to undoubtedly assign that the observed effect of LMG21717 supernatants upon 260 

\

was due to the production of these toxins, the same dose-effect experiment was 261 
R
?H
W
IHL?@ KFt> t>? BIB
-toxin producer ATCC43601 strain. Data obtained 262 
s
EJ
RR
C?L?BtAHD

F
O
JH?
X
AB@ EJ
RR
C?L?BtAHD
\
A
M
C? 
Z
E>IK?@ t>At t>? BIHLACF
U
?@
-CI 263 
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N
ACJ?E I
W
t>? 
\
 in presence of supernatants from this strain remained almost stable 264 
@JHF
ng the time course of the experiment (~ 22 h); thus non-toxigenic effect was 265 
@?t?Gt?@
 with a no toxin producing strain.  266 
Q
B A Et?
R W
JHt>?H
, we want to assess whether results obtained with strain 267 

X

X

 could be reproduced in another biological model. In this regard, Caco2 and 268 
HT29 cell lines have extensively being used in research to mimic the human intestinal 269 
epithelium. Under confluent and differentiated state both cell lines express characteristic 270 
of enterocytes, but Caco2 monolayers are composed exclusively of absorptive cells, 271 
whilst HT29 also includes mucus-secretory Goblet cells (Hilgendorf et al., 2000). Then 272 
in our study the IEC line Caco2 was confronted with the C. difficile toxigenic 273 
supernatant in percentages ranging from 10% to 0.16% (Fig. 4). Indeed, although we 274 
have observed a toxigenic effect of the C. difficile supernatant upon Caco2 monolayers, 275 
the normalized-CI values showed a different tendency with respect to that of HT29. 276 
After a short 4-h contact period, only concentrations of C. difficile supernatants higher 277 
than 1.25% were toxic; this cut-off percentage went down to 0.63% for prolonged co-278 
incubation period (Table 3). Therefore, the intrinsic characteristics of each IEC 279 
accounted for the development of a model to address the toxigenic effect of this 280 
pathogen.  281 
 282 
3.3. Visualization of C. difficile toxic effect 283 
Image analysis was performed in order to correlate with the events that are recorded 284 
with the RTCA technology. HT29 monolayers were tested with 2.5% C. difficile 285 
supernatant and several images were captured in real time over time (Fig. 5, and 286 
supplementary video). Initially, before the supernatant addition, HT29 cells displayed 287 
typical morphology of an intestinal monolayer with most adjacent cells well connected, 288 
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indicating that tight junctions and cytoskeleton are intact. In a short period after 289 
supernatant addition, around 2 h, the cells into the monolayer become to acquire a 290 
spherical shape and tend to detach from the adjacent ones. This is in agreement with the 291 
way of action of the toxins which disarray actin cytoskeleton and finally induce cell 292 
death.      293 
 294 
4. Discussion 295 
Treatment for CDI involves the use of antibiotics to eliminate the pathogen or, more 296 
recently, the restoration of the intestinal microbiota to avoid relapse (van Nood et al., 297 
2013) which is still a controversial issue limiting its widespread use. Novel, -alternative 298 
to antibiotics-, antimicrobial strategies towards C. difficile are currently under 299 
evaluation; for example, the use of other microbial-origin molecules such as 300 
bacteriocins (Gebhart et al., 2015) and bacteriophage endolysins (Dunne et al., 2014). 301 
Another less explored strategy is the use of drugs targeting C. difficile toxins which 302 
could act as co-adjuvants to palliate the acute effect induced by the pathogen (Tam et 303 
al., 2015). In this article, we report the optimization of a label-free, impedance-based 304 
RTCA method to follow the cytotoxicity kinetics of human colonocyte-like cells 305 
exposed to C. difficile supernatants, method that could be used for the screening of new 306 
toxin-activity inhibitors. Different label-free technologies, alternative to classic label-307 
based endpoint methods, are currently been used in different research fields such as 308 
evaluation of new drugs (Xi et al., 2008) and cancer development studies (Limame et al. 309 
2012), but also for assessment of the toxic effect of infectious bacteria upon host cells 310 
(Slanina et al., 2011; Ye et al., 2015). Specifically the RTCA technology, also known as 311 
RC-CES (real time-cell electronic sensing), was recently applied to develop methods 312 
allowing the clinical diagnosis of toxigenic C. difficile in different biological samples 313 
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sHuang et al., 2014a). For this purpose cell lines from non-intestinal origin were used, 314 
EJG> AE
HS27 cells (fibroblast) obtained from human skin (Huang et al., 2014b; Ryder 315 
et al., 2010), mRG1-1 cells genetically modified from CHO cells (epithelial 316 
morphology) which come from Hamster ovary (He et al., 2009; Steele et al., 2012) or 317 
Vero cells (epithelial morphology) obtained from a monkey kidney (Yu et al., 2015).  318 
However, given that the aim pursued in our work was to develop a method allowing the 319 
screening of new potential bio-actives against C. difficile toxicity acting within the 320 
human gut, we have choose as cellular model an intestinal epithelial line since 321 
enterocytes are the primary action targets of these toxins. Additionally, although the 322 
results obtained with HT29 cells in proliferative state were similar (data no shown), we 323 
worked in a confluent state (monolayer) because this better mimic the physiological 324 
conditions of an intestinal epithelium. 325 
 One of the remarkable findings observed in the context of our work was the fact 326 
that the culture media used to grow C. difficile under laboratory conditions had great 327 
influence in the release (secretion) of the toxins to the supernatant. Indeed, the non-328 
selective BHI medium, classically used for growing this bacterium, retained almost all 329 
toxigenic activity attached to the bacterial pellet, whereas the two media based on GAM 330 
were those more effective releasing the toxins. It has been reported that culture 331 
conditions, i.e. micro- and macronutrient composition, have strong influence in both 332 
induction and repression of toxin production (Lei et al., 2013). In fact it was proven that 333 
GILLIB
 rich media components, such as yeast or beef and pork peptones, are able to in 334 
vitro and in vivo inhibit the toxicity of C. difficile toxin A (Duncan et al., 2009). In 335 
addition, culture media also influence the composition of C. difficile protein secretome, 336 
including their toxins (Boetzke et al. 2012). The exact mechanism of TcdA and TcdB 337 
 ¡  ¢¡£¡ ¤¡, but it seems that secretion signals or bacterial lysis are not 338 
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¡
§
 
¨§

©ª «

¬
 mechanisms of toxin release, such as the formation of a holin-like 339 
protein, are still controversial (Govind et al., 2012; Olling et al., 2012). Therefore, to in 340 
vitro evaluate the efficacy of any potential toxin´s inhibitor, the laboratory C. difficile 341 
culture conditions must be carefully chosen. In this regard, our RTCA strategy allowed 342 
a fast, reliable and tailor-made method for the selection of culturing and toxin secretion 343 
conditions.  344 
 The data of cytotoxicity kinetics obtained from the dose-response curve showed 345 
an initial increase in the normalized-CI, which can be related with a modification in the 346 
morphology of the cells (Hidalgo-Cantabrana et al., 2014; Yu et al., 2006), followed by 347 
a drastic and continuous drop of this value during prolonged incubation times. 348 
Additionally, a strong dose-response behavior was detected with a good fit (R
2
 >0.99) to 349 
a sigmoid-curve allowing the calculation of different toxicological parameters (Jeffery 350 
et al., 2014). The lowest concentration at which our model of C. difficile supernatants 351 
induced a significantly toxic effect upon HT29 cells, after a short exposition-period (4 352 
h), was 164 and 12.5 pg/ml for toxin A and B, respectively. In this regard, it has been 353 
reported that TcdB is at least 100-fold more potent than TcdA upon other non-intestinal 354 
cell lines (Tan et al., 2015). Thus, our data confirm this ratio upon human colonocyte-355 
like cells. As far as we could achieve after an exhaustive literature search, there are not 356 
reports about the toxicity range of C. difficile culture supernatants upon HT29, or 357 
enterocyte-like cells, allowing comparison with the results obtained in this study. 358 
Regarding other cellular models, Ryder and co-workers (2010) have also detected a 359 
dose- and time-dependent effect of purified toxins upon HS27 cells, being the detection 360 
limit for toxin B ~200 pg/ml with a detection time between 15 to 18 h. They also 361 
succeed with the detection of toxigenic C. difficile in stool samples collected from 300 362 
CDI patients. This assay was improved latter when an immunomagnetic separation 363 
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enrichment process was incorporated during stool preparation (Huang et al., 2014b). In 364 
parallel, He and collaborators (2009) reported in mRG1-1 cells detection limits about 10 365 
pg/ml and 10 ng/ml for TcdB and TcdA, respectively, after prolonged (~ 20 h) 366 
incubation time.; the range of the latter decreased to 1-10 pg/ml if the assay is carried 367 
out in the presence of the anti-C. difficile toxin A monoclonal antibody A1H3, since the 368 
mRG1-1 cells were engineered to express the murine Fc gamma receptor (FcγRI)-α-369 
chain, thus increasing the sensitivity of the assay. The model develop by this group was 370 
also successfully used in the detection of toxins present in blood plasma of CDI animal 371 
models (Steele et al., 2012) and in two cases of human C. difficile toxemia (Yu et al., 372 
2015). These reports underlines that the detection limits are very dependent on the 373 
cellular model used, as well as on the preparation of complex biological samples.   374 
 Results obtained with our RTCA cytotoxic assay were confirmed with the 375 
images captured every 15-min with the time lapsed optical microscope. A time-376 
dependent cell rounding of HT29 cells was observed, which it is a typical 377 
morphological change observed in different cell lines treated with C. difficile toxins 378 
(Steele et al., 2012; May et al. 2013). This loss of shape is due to modification in the 379 
cellular cytoskeleton induced by the toxins, which are able to depolymerize or 380 
disassemble F-actins (May et al., 2013). Another label-free, end-point independent 381 
technology to measure cellular events involves the use of a lens-free, video microscopy 382 
platform (Kesavan et al., 2014). The image-monitoring in real time records similar 383 
events than those measured by the impedance-based RTCA, such cell adhesion, 384 
spreading, division and death. Indeed, this alternative high-throughput imaging-based 385 
methodology was also used to identify new C. difficile TcdB inhibitors that protected 386 
human (non-enterocyte) cells, in this case CHO, Vero and IMR-90, from cell rounding 387 
(Tan et al., 2015).     388 
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Finally, is worth noting that the cellular model used to carry out cytotoxic 389 
¯

¯°
, even if the cells are from the same tissue type, had an impact on the results 390 
obtained; we have previously observed similar findings in other types of studies using 391 
different IEC lines (Hidalgo-Cantabrana et al., 2014). In relation to the aim of the 392 
current work, this cell-dependent effect is especially relevant to test the efficacy of any 393 
potential anti-toxin bioactive since toxicological parameters, such as EC50 or LOAEL, 394 
can vary. Thus, although a broad screening can be performed with a single cell line, it 395 
would be advisable the use of more than one cellular type for the definition of the 396 
efficacy range of any novel candidate to inhibit C. difficile toxic activity.  397 
 398 
5. Conclusion 399 
In this work we have developed a valuable in vitro model to test cytotoxicity kinetics of 400 
C. difficile supernatants upon IEC, which could be eventually used in the screening of 401 
new anti-CDI agents. The model allows the preliminary selection of the appropriate 402 
culture conditions, as well as the choice of the accurate doses, to undertake the further 403 
toxicological assays of C. difficile toxins. However, it must be taken into consideration 404 
the variability of the results related to the model of eukaryotic cell used to analyze 405 
cytotoxicity. In addition, we consider that this model could be extended to the study of 406 
other microbial cyto-toxins.  407 
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Table 1. Composition of culture media used to select the best conditions for growth and 537 
toxin production of Clostridium difficile LMG21717. 538 
·¸¹º»¼ ½¾¼¿¾ÀºÁº¾Â ÃÄÅÂ¹s
Æ
ÇÈÉ ÊËÌÍÍÎÏÐÏÑÒÓÔÕ ÒÓÖÎÏ ×ØÙ ÚÛÜÝÞ 
ßàá ÊËÌÍÍÎÏÐÏÑÒÓÔÕ ÒÓÖÎÏ ×ØÙ ÚÛÜÝÞ 
âãÉ ÊËÌÍÍÎÏÐÏÑÒÓÔÕ ÒÓÖÎÏ ×ØÙ äÝËËÌÝ 
ÇÈÉåßàáåæ×ß Ø çol RCM + 1 vol BHI + Foetal Serum Bovine (5%) ÚÛÜÝÞè ×ÝéÐÓ 
ßàá-C ßàá å ê-cysteine (0.25%) ÚÛÜÝd, Sigma 
ßàáëSuppl. ßàá å êëcysteine (0.25%) + yeast extract (0.5%) + 
ËÜÞÝÌÐ ÒìÝÜéÎÕíÜÎÓÒÏ ÊîïØðÙ 
ÚÛÜÝÞè BD-ñÝòíÜè
Sigma 
ßàá-C-FSB ßàá å ê-cysteine (0.25%) + Foetal Serum Bovine (5%) ÚÛÜÝd, Sigma 
âãÉëFSB âãÉ å æÜÏÒÓÎ ×ÏÔÌÐ ßÜçÝÑÏ ÊóðÙ äÝËËÌÝè ×igma
ô Oxoid, Thermo Fisher Scientific Inc., Waltham, MA; Nissui Pharmaceutical Co., Ltd., Tokyo, Japan; 539 
Sigma-Aldrich Co., St. Louis, MO; BD-Difco, Becton Dickinson Co., Franklin Lakes, NJ.  540 
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Table 2 Cultures of Clostridium difficile LMG21717, after 48 h of incubation, made in 542 
different media used to select the best conditions for growth and toxigenic activity. The 543 
highest toxigenic activity was established at the lowest normalized-cell index (CI) value 544 
obtained from the intestinal cell lines HT29 and Caco2 after 4 h of C. difficile factors 545 
addition.  546 
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Table 3 Normalized-cell index (CI) values obtained from the intestinal cell lines HT29 549 
and Caco2 after 4 h and 22 h of addition of different concentrations of Clostridium 550 
difficile LMG21717 toxigenic supernatants.  551 
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Figure legend 554 
FIG. 1 Titration of HT29 and Caco2 cells dependent on the initial number of cells 555 
seeded (A). Experimental design used to test the toxic effect of C. difficle LMG21717 556 
(B) and microscopic visualization of the HT29 cell morphology immediately after 557 
seeding (left microphotograph) and when the confluent monolayer state was reached 558 
(right microphotograph).   559 
 560 
FIG. 2 Behaviour of HT29 monolayers in the presence of the toxigenic supernatants 561 
and pellets collected from C. difficile cultures grown for 48 h in different culture media. 562 
Normalized cell index (CI) obtained from E-plates to test McCoy´s medium 563 
supplemented with 20% of supernatants from each medium (A) or with pellets 564 
resuspended (1/10 vol. of the initial 48-h culture) in McCoy´s medium (B). The CI was 565 
normalized by the control (non-supplemented McCoy´s medium) sample at the time of 566 
the supernatant or pellet addition. Normalized-CI values 4-h after addition of factors 567 
obtained from 48, 72 and 120 h of C. difficile cultures in media containing GAM (C). 568 
 569 
FIG. 3 Behaviour of HT29 monolayers in the presence of different percentages of the 570 
toxigenic supernatant collected from C. difficile cultures grown for 48 h in GAM. Mean 571 
values of data after normalization of the CI by the control sample (non-supplemented 572 
369:;´s medium) and by the time of the supernatant addition (A). Dose-response data 573 
(mean and SD) fitted to a sigmoidal trend line curve allowing the identification of the 574 
EC50 (concentration where supernatant produced 50% of the maximum toxic effect), 575 
LOAEL (lowest observed adverse effect level, p<0.05) and NOAEL (non-observed 576 
a=>?@A? ?DD?
6
E F?>?FI doses (B).  577 
  578 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
2J 
 
FIG. 4 Behaviour of Caco2 monolayers in the presence of different percentages of the 579 
toxigenic supernatant collected from C. difficile cultures grown for 48 h in GAM. The 580 
CI was normalized by the control (non-supplemented DMEM) sample at the time of the 581 
supernatant addition. 582 
 583 
FIG. 5 Visualization over time (from 0 to 24 h, photo-capture interval of 1h, 40 min) 584 
under inverted optical microscope (objective x40) of the HT29 monolayer in the 585 
presence of 2.5% C. difficile toxigenic supernatant collected from 48 h cultures in GAM 586 
medium. Arrows indicate some areas of monolayer disaggregation. (See Supplementary 587 
video, made with a selection of 100 microphotographs captured at 10 min interval, from 588 
0 to 24 h).  589 
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